Comparison of plasma pharmacokinetics and bioequivalence of ceftiofur sodium in cattle after a single intramuscular or subcutaneous injection

2000 ◽  
Vol 23 (5) ◽  
pp. 273-280 ◽  
Author(s):  
S. A. Brown ◽  
S. T. Chester ◽  
A. K. Speedy ◽  
V. L. Hubbard ◽  
J. K. Callahan ◽  
...  
Keyword(s):  
Subcutaneous Injection ◽  
Plasma Pharmacokinetics ◽  
Ceftiofur Sodium

scholarly journals Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis

Pharmaceutics ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 265 ◽  
Author(s):  
Richard G. Pearson ◽  
Tahir Masud ◽  
Elaine Blackshaw ◽  
Andrew Naylor ◽  
Michael Hinchcliffe ◽  
...  
Keyword(s):  
Nasal Spray ◽  
Subcutaneous Injection ◽  
Relative Bioavailability ◽  
Nasal Delivery ◽  
Absolute Bioavailability ◽  
Preclinical Model ◽  
Permeation Enhancer ◽  
Treatment Of Osteoporosis ◽  
Plasma Pharmacokinetics ◽  
Spray Formulation

Nasal delivery of large peptides such as parathyroid 1-34 (PTH 1-34) can benefit from a permeation enhancer to promote absorption across the nasal mucosa into the bloodstream. Previously, we have published an encouraging bioavailability (78%), relative to subcutaneous injection in a small animal preclinical model, for a liquid nasal spray formulation containing the permeation enhancer polyethylene glycol (15)-hydroxystearate (Solutol® HS15). We report here the plasma pharmacokinetics of PTH 1-34 in healthy human volunteers receiving the liquid nasal spray formulation containing Solutol® HS15. For comparison, data for a commercially manufactured teriparatide formulation delivered via subcutaneous injection pen are also presented. Tc-99m-DTPA gamma scintigraphy monitored the deposition of the nasal spray in the nasal cavity and clearance via the inferior meatus and nasopharynx. The 50% clearance time was 17.8 min (minimum 10.9, maximum 74.3 min). For PTH 1-34, mean plasma Cmax of 5 pg/mL and 253 pg/mL were obtained for the nasal spray and subcutaneous injection respectively; relative bioavailability of the nasal spray was ≤1%. Subsequently, we investigated the pharmacokinetics of the liquid nasal spray formulation as well as a dry powder nasal formulation also containing Solutol® HS15 in a crossover study in an established ovine model. In this preclinical model, the relative bioavailability of liquid and powder nasal formulations was 1.4% and 1.0% respectively. The absolute bioavailability of subcutaneously administered PTH 1-34 (mean 77%, range 55–108%) in sheep was in agreement with published human data for teriparatide (up to 95%). These findings have important implications in the search for alternative routes of administration of peptides for the treatment of osteoporosis, and in terms of improving translation from animal models to humans.

Pharmacokinetics of ceftiofur sodium in cats following a single intravenous and subcutaneous injection

2019 ◽  
Vol 42 (6) ◽  
pp. 602-608
Author(s):  
Mei Zhang ◽  
Fang Yang ◽  
Hua‐jie Yu ◽  
Tian‐jing Kang ◽  
Yong‐hui Ding ◽  
...  
Keyword(s):  
Subcutaneous Injection ◽  
Ceftiofur Sodium

Pharmacokinetics of ceftiofur sodium in Peekapoo dogs following a single intravenous and subcutaneous injection

2020 ◽  
Vol 43 (4) ◽  
pp. 325-330 ◽  
Author(s):  
Fang Yang ◽  
Fan Yang ◽  
Han Wang ◽  
Chao‐Shuo Zhang ◽  
Zhe‐Wen Song ◽  
...  
Keyword(s):  
Subcutaneous Injection ◽  
Ceftiofur Sodium

Comparative plasma pharmacokinetics of ceftiofur sodium and ceftiofur crystalline-free acid in neonatal calves

2015 ◽  
Vol 39 (3) ◽  
pp. 271-276 ◽  
Author(s):  
J. S. Woodrow ◽  
M. Caldwell ◽  
S. Cox ◽  
M. Hines ◽  
B. C. Credille
Keyword(s):  
Free Acid ◽  
Plasma Pharmacokinetics ◽  
Neonatal Calves ◽  
Ceftiofur Sodium

A SUBCUTANEOUS INJECTION ASSAY FOR ANTI-ANDROGENS IN THE CHICK

1962 ◽  
Vol 41 (2) ◽  
pp. 268-273 ◽  
Author(s):  
Ralph I. Dorfman
Keyword(s):  
Dose Response ◽  
Subcutaneous Injection ◽  
Response Relationship ◽  
Dose Response Relationship

ABSTRACT The stimulating action of testosterone on the chick's comb can be inhibited by the subcutaneous injection of 0.1 mg of norethisterone or Ro 2-7239 (2-acetyl-7-oxo-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahydrophenanthrene), 0.5 mg of cortisol or progesterone, and by 4.5 mg of Mer-25 (1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol). No dose response relationship could be established. Norethisterone was the most active anti-androgen by this test.

Sign in / Sign up

Export Citation Format

Share Document